Wildcat Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Wildcat Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,500	Closed	-$55K	–	12
2017 Q3	$55K	Hold	1,500	–	–	0.01%	16
2017 Q2	$38K	Hold	1,500	–	–	0.01%	18
2017 Q1	$41K	Hold	1,500	–	–	0.01%	15
2016 Q4	$44K	Buy	+1,500	New	+$49K	0.02%	14
2016 Q3	–	Sell	-1,500	Closed	-$47K	–	24
2016 Q2	$47K	Sell	1,500 -22,026	-94%	-$995K	0.02%	18
2016 Q1	$1.22M	Hold	23,526	–	–	0.42%	17
2015 Q4	$2.24M	Sell	23,526 -1,500	-6%	-$132K	0.63%	13
2015 Q3	$2.06M	Buy	25,026 +1,500	+6%	+$192K	0.77%	9
2015 Q2	$3.82M	Buy	+23,526	New	+$7.94M	1.31%	9

Other funds holding ADVM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Wildcat Capital Management's ADVM Position: Q4 2017 in Review

Wildcat Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2017, closing a stake of 1,500 shares — an estimated $55K sold.

Wildcat Capital Management first reported a position in ADVM in Q2 2015 and held it in 9 quarters. The position peaked at $3.82M in Q2 2015. 65 funds tracked by Wall St. Rank hold ADVM as of Q4 2017.

Wildcat Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2017 after selling out during the quarter.
Wildcat Capital Management sold 1,500 Adverum Biotechnologies shares in Q4 2017, an estimated $55K.
Wildcat Capital Management first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 9 quarters.
Wildcat Capital Management's Adverum Biotechnologies position peaked at $3.82M in Q2 2015.
65 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2017.

Based on Wildcat Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.